周五报道，Foghorn Therapeutics获得5000万美元股权融资，推进肿瘤学管道，并将2.089亿美元现金流延长至2028年上半年

2026-01-12 16:37

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026
Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Selective CBP degrader program with potential in ER+ breast cancer on track to be IND-ready in 2026
Selective EP300 degrader program shows preclinical superior anti-tumor efficacy and tolerability over dual CBP/EP300; tracking to IND-enabling studies in 2026
Strong balance sheet with cash, cash equivalents, and marketable securities of $208.9 million*, including proceeds from the equity financing, which is anticipated to close on January 13, 2026, and allows for continued investment in the pipeline and extends cash into the first half of 2028